GlobeNewswire Inc.T3·12mo ago
IMA ImageneBio, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
IMA
—
—
Key stats
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 18
- List Date
- 2025-07-28
- CIK
- 0001835579
- Next Earnings
- 2026-11-11
- EPS Forecast
- ($0.83) (3 est.)
- Headquarters
- San Diego, CA
- Homepage
- https://www.imagenebio.com
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '25 | '26 | Avg |
|---|---|---|---|
| Jan | -- | 11.09% | 11.09% |
| Feb | -- | -5.22% | -5.22% |
| Mar | -- | -21.51% | -21.51% |
| Apr | -- | 19.21% | 19.21% |
| May | -- | 3.89% | 3.89% |
| Jun | -- | 7.86% | 7.86% |
| Jul | 9.35% | -4.48% | 2.43% |
| Aug | -22.45% | -9.57% | -16.01% |
| Sep | -39.00% | -8.76% | -23.88% |
| Oct | 2.35% | -11.57%* | -4.61% |
| Nov | -17.86% | -- | -17.86% |
| Dec | 2.99% | -- | 2.99% |
| Total | -55.21% | -23.06% | -39.14% |
* Only 2 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $4.30
SMA 50: $4.79
SMA 200: $5.69
Current: $4.05
EMA 12: $4.17
EMA 26: $4.39
MACD: -0.2161 | Signal: 0.0144
BEARISH
ADX (14): 33.12
TREND
+DI: 16.48
−DI: 18.91
Momentum Oscillators
RSI (14): 33.91
NEUTRAL
Stoch %K: 26.59
Stoch %D: 25.12
Williams %R: -76.71
Volume & Volatility
BB Upper: $4.78
BB Lower: $3.82
NEUTRAL
OBV: 17,112,468
Vol SMA 20: 13,572
Vol ROC: 17.27%
ATR: $0.24
True Range: $0.54
HV 20: 40.9%
HV 30: 36.8%
HV 60: 36.3%
Data Summary
Data Points: 315
Last Updated:
Date Range: 2025-07-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL with confidence level (6)
Key drivers:
- Technical indicators pointing to a consolidation phase
- Recent news headlines highlighting clinical trial developments for OX40 Targeted Therapy, which could impact the stock price
Primary risks:
- Regulatory hurdles in the pharmaceutical industry
- Competition from established players in the same space
Investment thesis: IMA's recent performance is influenced by its involvement in clinical trials and regulatory approvals. The company's growth prospects are closely tied to the success of these initiatives.
Recent news sentiment impact: Positive, as the announcement of clinical trial developments has generated excitement among investors and analysts.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - NEUTRAL, Medium-term (1-3 months) - BEARISH, Long-term (3-12 months) - BULLISH
Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- SMA 20: $5.70
- SMA 50: $5.57
- SMA 200: $7.48
- Resistance: Upper Bollinger Band ($6.13)
- Support: Lower Bollinger Band ($5.27)
Momentum Signals:
- RSI interpretation (neutral): 51.41
- MACD signal (bearish): -0.04 / Signal: -0.02 / Histogram: -0.02
- Bollinger Bands position (squeeze): Neutral
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles:
- Clinical trial developments for OX40 Targeted Therapy
- Regulatory approvals and industry trends
Sentiment Assessment: Aggregate news sentiment: POSITIVE
Catalyst Identification: Upcoming events, earnings, product launches, regulatory changes:
- Earnings announcement (TBD)
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market (beta): 0.87 (vs SPY) - moderate volatility
Volatility Regime: Current vs historical volatility levels: HV20 67.3% / HV30 60.7% / HV60 72.1%
Options Market Signals: IV rank: N/A, put/call ratios: N/A, unusual activity: N/A
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- Pharmaceuticals: WEAKENING
- Biotechnology: MIXED
Institutional Activity: Volume patterns suggesting institutional interest:
- On-Balance Volume (OBV): 17503245.97 (upward)
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- Correlation: 0.14 - moderate correlation with the broader market
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- SMA 20: $5.70
- SMA 50: $5.57
- SMA 200: $7.48
- Resistance: Upper Bollinger Band ($6.13)
- Support: Lower Bollinger Band ($5.27)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Upper Bollinger Band ($6.13) - breakout potential
- Lower Bollinger Band ($5.27) - breakdown potential
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- Earnings announcement (TBD)
Risk Management: Stop-loss levels and position sizing considerations:
- Risk level: MODERATE
- Potential stop-loss levels:
- Upper Bollinger Band ($6.13)
- SMA 50: $5.57
Generated
News
All IMA news →
Earnings History
1 of 1 under expected move
Avg Expected Move
—
Avg Actual Move
0.00%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-08-06 | unknown | — | 0.00% | — | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
IMA Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.0062
Alpha: -65.50%
Correlation: 0.2242
R-Squared: 5.0%
Stock Volatility: 57.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own IMA
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $513K | #2603 of 3138 | +6.4% | 13F | |
| Citadel Hedge fund Ken Griffin | $328K | #4969 of 6285 | -55.3% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
IMA Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
IMA Insider Trading (Form 4)
Latest: 2026-08-17Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Yanina Grant-Huerta | Chief Financial Officer | Award (A) | +104,000 | — | EDGAR | |
| 2026-08-17 | Kristin Yarema | Chief Executive Officer | Award (A) | +254,800 | — | EDGAR | |
| 2026-07-28 | Kristin Yarema | Chief Executive Officer | Mixed | +153,505 | — | EDGAR | |
| 2026-07-20 | Robert B Lally | Principal Accounting Officer | Sell (S) | −3,196 | $5.42 | -$17.3K | EDGAR |
| 2026-06-18 | Joseph P Slattery | Director | Grant (A) | +15,600 opt | — | EDGAR | |
| 2026-06-18 | Otello Stampacchia | Director | Grant (A) | +15,600 opt | — | EDGAR | |
| 2026-06-18 | David P Bonita | Director | Grant (A) | +15,600 opt | — | EDGAR | |
| 2026-06-18 | Jonathan Jian Wang | Director | Grant (A) | +15,600 opt | — | EDGAR | |
| 2026-04-16 | OrbiMed Genesis GP LLC | Director | Buy (P) | — | — | EDGAR | |
| 2026-04-16 | David P Bonita | Director | Buy (P) | — | — | EDGAR | |
| 2026-03-18 | Kristin Yarema | Chief Executive Officer | Award (A) | +85,400 | — | EDGAR | |
| 2026-01-02 | Erin Butler | Principal Accounting Officer | Award (A) | +22,500 | — | EDGAR | |
| 2025-12-29 | Joseph P Slattery | Director | Buy (P) | +16,000 | $5.99 | $95.8K | EDGAR |
| 2025-12-22 | Joseph P Slattery | Director | Grant (A) | +31,200 opt | — | EDGAR | |
| 2025-12-22 | Stephen Hui Wang | Director | Grant (A) | +31,200 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
IMA Insider Holdings
11 insiders · @ $4.05
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jonathan Jian Wang | Director | 1,115,005 | $4.52M | $0 | 3 | 2026-06-18 |
| 2 | David P Bonita | Director | 753,441 | $3.05M | $2.50M | 3 | 2026-06-18 |
| 3 | OrbiMed Genesis GP LLC | Director | 753,062 | $3.05M | $0 | 2 | 2026-04-16 |
| 4 | Kristin Yarema | Chief Executive Officer | 493,705 | $2.00M | $0 | 4 | 2026-08-17 |
| 5 | Otello Stampacchia | Director | 455,361 | $1.84M | $8.00M | 2 | 2026-06-18 |
| 6 | Yanina Grant-Huerta | Chief Financial Officer | 65,000 | $263.2K | $0 | 1 | 2026-08-17 |
| 7 | Robert B Lally | Principal Accounting Officer | 55,582 | $225.1K | -$17.3K | 1 | 2026-07-20 |
| 8 | Erin Butler | Principal Accounting Officer | 25,551 | $103.5K | $0 | 2 | 2026-01-02 |
| 9 | Joseph P Slattery | Director | 16,000 | $64.8K | $95.8K | 3 | 2026-06-18 |
| 10 | Stephen Hui Wang | Director | 12,535 | $50.8K | $0 | 2 | 2025-12-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
IMA Board & Officers
As of SEC filings through Aug 17, 2026Directors 12
- David P Bonita · since Mar 25, 2021
- Iain D. Dukes · since Mar 25, 2021
- OrbiMed Capital GP VI LLC (entity) · since Mar 25, 2021
- OrbiMed Genesis GP LLC (entity) · since Mar 25, 2021
- Orbimed Advisors LLC (entity) · since Mar 25, 2021
- Otello Stampacchia · since Mar 25, 2021
- Maria Koehler · since Apr 15, 2021
- Jonathan Jian Wang · since Jul 25, 2025
- Kristin Yarema · since Jul 25, 2025
- Stephen Hui Wang · since Jul 25, 2025
- Joseph P Slattery · since Nov 1, 2025
- Wei-guo Su · since Apr 16, 2026
Officers 4
- Kristin Yarema · Chief Executive Officer · since Jul 25, 2025
- Yanina Grant-Huerta · Chief Financial Officer · since Jul 20, 2026
- Benjamin Porter-Brown · Chief Medical Officer · since Feb 16, 2026
- Robert B Lally · Principal Accounting Officer · since Mar 20, 2026
Changes in the last 10 years (48)
| Jul 20, 2026 | Yanina Grant-Huerta became Chief Financial Officer |
| Apr 16, 2026 | Wei-guo Su became a director |
| Mar 20, 2026 | Robert B Lally became Principal Accounting Officer |
| Mar 12, 2026 | The company announced the departure of Erin Butler as Principal Accounting Officer in an SEC filing |
| Feb 16, 2026 | Benjamin Porter-Brown became Chief Medical Officer |
| Dec 12, 2025 | The company announced the departure of Yufang Lu as Chief Medical Officer in an SEC filing |
| Nov 1, 2025 | Joseph P Slattery became a director |
| Jul 29, 2025 | Jotin Marango reported in an SEC filing no longer being CFO & Head of Corp. Dev. |
| Jul 25, 2025 | Yufang Lu became Chief Medical Officer |
| Jul 25, 2025 | Stephen Hui Wang became a director |
| Jul 25, 2025 | Kristin Yarema became a director |
| Jul 25, 2025 | Kristin Yarema became Chief Executive Officer |
| Jul 25, 2025 | Jonathan Jian Wang became a director |
| Jul 25, 2025 | Erin Butler became Principal Accounting Officer |
| Feb 29, 2024 | Caroline Germa became Chief Medical Officer |
| Feb 20, 2024 | The company announced the departure of Sergio L. Santillana as Chief Medical Officer in an SEC filing |
| Dec 15, 2022 | The company announced the departure of Ronald C Renaud JR from the board in an SEC filing |
| Dec 14, 2022 | Owen Hughes became a director |
| Apr 25, 2022 | Jotin Marango became CFO & Head of Corp. Dev. |
| Feb 18, 2022 | Francisco Oliveira became Principal Accounting Officer |
| Feb 4, 2022 | Jeffrey Ecsedy listed as Chief Development Officer (previously Chief Scientific Officer) in SEC filings |
| Jan 28, 2022 | The company announced the departure of Douglas R Carlson as COO & EVP of Finance in an SEC filing |
| Jan 21, 2022 | Richard Wooster became a director |
| Nov 22, 2021 | Xiaoyan Michelle Zhang became Chief Scientific Officer |
| Apr 15, 2021 | Maria Koehler became a director |
| Mar 25, 2021 | Sergio L. Santillana became Chief Medical Officer |
| Mar 25, 2021 | Ronald C Renaud JR became a director |
| Mar 25, 2021 | Otello Stampacchia became a director |
| Mar 25, 2021 | Orbimed Advisors LLC became a director |
| Mar 25, 2021 | OrbiMed Genesis GP LLC became a director |
| Mar 25, 2021 | OrbiMed Capital GP VI LLC became a director |
| Mar 25, 2021 | Maude Tessier became Chief Business Officer |
| Mar 25, 2021 | Mark Manfredi became a director |
| Mar 25, 2021 | Mark Manfredi became President & CEO |
| Mar 25, 2021 | Jeffrey Ecsedy became Chief Scientific Officer |
| Mar 25, 2021 | Jean Francois Formela became a director |
| Mar 25, 2021 | Iain D. Dukes became a director |
| Mar 25, 2021 | Douglas R Carlson became COO & EVP of Finance |
| Mar 25, 2021 | David P Bonita became a director |
| Mar 25, 2021 | Atlas Venture Opportunity Fund I, L.P. became a 10% owner |
| Mar 25, 2021 | Atlas Venture Fund XI, L.P. became a 10% owner |
| Mar 25, 2021 | Atlas Venture Fund X, L.P. became a 10% owner |
| Mar 25, 2021 | Atlas Venture Associates XI, LLC became a 10% owner |
| Mar 25, 2021 | Atlas Venture Associates XI, L.P. became a 10% owner |
| Mar 25, 2021 | Atlas Venture Associates X, LLC became a 10% owner |
| Mar 25, 2021 | Atlas Venture Associates X, L.p. became a 10% owner |
| Mar 25, 2021 | Atlas Venture Associates Opportunity I, LLC became a 10% owner |
| Mar 25, 2021 | Atlas Venture Associates Opportunity I, L.P. became a 10% owner |
Not reported recently (18)
- Jean Francois Formela · Last reported as a director in an SEC filing dated Jun 10, 2024
- Richard Wooster · Last reported as a director in an SEC filing dated Jun 10, 2024
- Owen Hughes · Last reported as a director in an SEC filing dated Jun 10, 2024
- Mark Manfredi · Last reported as a director in an SEC filing dated Jun 7, 2024
- Caroline Germa · Last reported as Chief Medical Officer in an SEC filing dated Mar 5, 2024
- Jeffrey Ecsedy · Last reported as Chief Development Officer in an SEC filing dated Feb 2, 2024
- Xiaoyan Michelle Zhang · Last reported as Chief Scientific Officer in an SEC filing dated Jan 5, 2023
- Francisco Oliveira · Last reported as Principal Accounting Officer in an SEC filing dated Feb 24, 2022
- Maude Tessier · Last reported as Chief Business Officer in an SEC filing dated Feb 4, 2022
- Atlas Venture Fund XI, L.P. · Last reported as a 10% owner in an SEC filing dated Dec 14, 2021
- Atlas Venture Associates Opportunity I, L.P. · Last reported as a 10% owner in an SEC filing dated Dec 14, 2021
- Atlas Venture Associates Opportunity I, LLC · Last reported as a 10% owner in an SEC filing dated Dec 14, 2021
- Atlas Venture Associates XI, L.P. · Last reported as a 10% owner in an SEC filing dated Dec 14, 2021
- Atlas Venture Associates XI, LLC · Last reported as a 10% owner in an SEC filing dated Dec 14, 2021
- Atlas Venture Opportunity Fund I, L.P. · Last reported as a 10% owner in an SEC filing dated Dec 14, 2021
- Atlas Venture Associates X, LLC · Last reported as a 10% owner in an SEC filing dated Apr 1, 2021
- Atlas Venture Fund X, L.P. · Last reported as a 10% owner in an SEC filing dated Apr 1, 2021
- Atlas Venture Associates X, L.p. · Last reported as a 10% owner in an SEC filing dated Apr 1, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold IMA
3 shown · $1.56M total exposure · 0.01% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.